Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Califf

Showing results (491-500 of 565) with videos related to

Pageof 57
Sort By:
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
European Journal of Heart Failure|March 2, 2006
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunctionLars Køber, Karl Swedberg, John J V McMurray, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
European Heart Journal|March 1, 2008
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT studyEldrin F Lewis, Eric J Velazquez, Scott D Solomon, et al.
Journal of Cardiac Failure|October 10, 2020
Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart FailureMarat Fudim, Joseph B Lerman, Courtney Page, et al.
The New England Journal of Medicine|November 12, 2003
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothMarc A Pfeffer, John J V McMurray, Eric J Velazquez, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Circulation. Cardiovascular Quality and Outcomes|June 30, 2011
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trialsPierluigi Tricoci, L Kristin Newby, Vic Hasselblad, et al.
International Journal of Cardiology|February 21, 2012
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 yearsMark Y Chan, Jie-Lena Sun, L Kristin Newby, et al.
Circulation|July 23, 2003
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular diseaseEric J Topol, Donald Easton, Robert A Harrington, et al.
Pageof 57

Showing results (491-500 of 565) with videos related to

Sort By:
Pageof 57
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
European Journal of Heart Failure|March 2, 2006
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunctionLars Køber, Karl Swedberg, John J V McMurray, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
European Heart Journal|March 1, 2008
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT studyEldrin F Lewis, Eric J Velazquez, Scott D Solomon, et al.
Journal of Cardiac Failure|October 10, 2020
Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart FailureMarat Fudim, Joseph B Lerman, Courtney Page, et al.
The New England Journal of Medicine|November 12, 2003
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothMarc A Pfeffer, John J V McMurray, Eric J Velazquez, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Circulation. Cardiovascular Quality and Outcomes|June 30, 2011
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trialsPierluigi Tricoci, L Kristin Newby, Vic Hasselblad, et al.
International Journal of Cardiology|February 21, 2012
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 yearsMark Y Chan, Jie-Lena Sun, L Kristin Newby, et al.
Circulation|July 23, 2003
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular diseaseEric J Topol, Donald Easton, Robert A Harrington, et al.
Pageof 57